Achieve Life Sciences (ACHV) vs CorMedix (CRMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Achieve Life Sciences (ACHV) has outperformed CorMedix (CRMD) over the past year, gaining 51.9% versus a loss of 28.7%. Over five years, CRMD leads with a +52.8% price change compared with -20.4% for ACHV. Achieve Life Sciences is the larger company by market cap ($657.8 million vs $565.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACHV | CRMD |
|---|---|---|
| Share price | $6.38 | $7.26 |
| Market cap | $657.79M | $565.88M |
| 1-day change | -8.46% | -2.68% |
| YTD return | +28.37% | -37.58% |
| 1-year return | +51.90% | -28.68% |
| 5-year return | -20.45% | +52.84% |
| P/E ratio (TTM) | — | 3.54 |
| Forward P/E | — | 20.74 |
| EPS (TTM) | $-1.69 | $2.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $311.71M |
| Revenue growth (YoY) | — | +617.03% |
| Net income (latest FY) | $-54.65M | $163.06M |
| Gross margin | — | 88.46% |
| Operating margin | — | 48.17% |
| Net margin | — | 52.31% |
| 52-week high | $8.64 | $13.02 |
| 52-week low | $2.62 | $6.13 |
| Distance from 52-week high | -26.16% | -44.24% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +121.79% | +111.16% |
| Average volume | 1.41M | 1.11M |
| Shares outstanding | 103.10M | 77.94M |
| Employees | 28 | 191 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACHV has outperformed CRMD by 80.6 percentage points over the past year.
About Achieve Life Sciences
ACHV stock →Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Healthcare · Biotechnology · 28 employees
About CorMedix
CRMD stock →CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Healthcare · Biotechnology · 191 employees
ACHV vs CRMD FAQ
Which is bigger, Achieve Life Sciences or CorMedix?
Achieve Life Sciences (ACHV) is larger, with a market capitalization of $657.79M compared with $565.88M for CorMedix (CRMD).
Which stock has performed better over the past year, ACHV or CRMD?
ACHV returned +51.90% over the past 12 months, compared with -28.68% for CRMD (price return, excluding dividends). Past performance does not predict future results.
Are Achieve Life Sciences and CorMedix in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.